Hemostatic Material Using Covalently Coupled TRAPs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hemostatic materials face limitations such as high cost, short shelf-life, mechanical weakness, and safety concerns due to the use of fibrin-based products, zeolite-induced burns, and thrombin's instability and potential for apoptosis, highlighting the need for alternative materials that avoid highly concentrated thrombin and ensure safe, localized hemostasis.
Innovation Solution
A hemostatic material is developed by covalently coupling thrombin receptor activating peptides (TRAPs) to a biocompatible matrix, specifically a synthetic hydrogel like polyvinyl alcohol, to maintain platelet activation activity over time without systemic thrombotic risks, using bioorthogonal reactions for efficient and specific coupling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thrombin is used in high concentration for hemostasis, then hemostatic effect is improved, but safety risks increase due to potential systemic thrombotic events and apoptosis
Solution Approach 1:
The patent applies local quality by immobilizing thrombin onto a porous matrix material, creating a localized reservoir that releases thrombin only at the application site. This ensures high local concentration for effective hemostasis while preventing systemic circulation and thrombotic events. The thrombin is activated only when in contact with blood at the wound site, maintaining safety while achieving reliability.
Solution Approach 2:
The patent implements preliminary action by pre-immobilizing thrombin onto the matrix material during manufacturing, so that the hemostatic agent is already in place and ready for immediate localized activation upon blood contact. This eliminates the need for high-dose systemic administration while ensuring the thrombin is available exactly where and when needed.
2Ease of manufacture
If hemostatic agents are physically adsorbed on matrix, then ease of manufacture is improved, but durability worsens due to easy release of agents
Solution Approach 1:
The patent uses composite materials by combining thrombin with a porous matrix material through covalent bonding or strong interaction. This creates a stable composite structure where the thrombin remains firmly attached to the matrix, preventing premature release while maintaining the porosity needed for blood contact and activation. The composite structure ensures both durability and functionality.
3Stability of the object's composition
If covalent coupling of thrombin to matrix is performed, then durability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs an intermediary approach by using carrier proteins or linkers that facilitate the coupling between thrombin and the matrix material. These intermediaries simplify the covalent coupling process while ensuring stable attachment, reducing manufacturing complexity compared to direct covalent bonding methods. The intermediary layer protects thrombin's activity while enabling firm attachment to the matrix.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The material effectively induces localized platelet aggregation and hemostasis, avoiding the drawbacks of existing products by retaining thrombin receptor activity and ensuring biocompatibility, stability, and safety, with potential for improved wound healing and surgical applications.
Implementation Method 1
a thrombin receptor activating agent is covalently coupled to a biocompatible matrix
Implementation Method 2
maintaining the activity for platelet activation in a safe, localized manner over a considerable period of time so as to enable an improved hemostasis, especially via an induced platelet aggregation
Data Source
Figure 1A
Figure 1B
Figure 1C~1D
AI summary
Disclosed is a hemostatic material, wherein a thrombin receptor activating agent is covalently coupled to a biocompatible matrix.